search
Back to results

Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement

Primary Purpose

Rotavirus Gastroenteritis

Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
Anti-rotavirus protein
Maltodextrin
Sponsored by
Christian Medical College, Vellore, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rotavirus Gastroenteritis

Eligibility Criteria

6 Months - 12 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year
  • Normal birth weight (> 2.5 kg), child exclusively breast fed for at least four months

Exclusion Criteria:

  • Families not available for a follow up period of one year
  • Children with any atopic conditions
  • Children with gross congenital anomalies including cardiovascular, renal or hepatic disease
  • Children with syndromic or serological evidence of HIV infection

Sites / Locations

  • Christian Medical College

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Anti-rotavirus protein

Maltodextrin

Arm Description

Outcomes

Primary Outcome Measures

Incidence of rotavirus gastroenteritis

Secondary Outcome Measures

IgA And IgG Antibody Response To Rotavirus
Weight For Height Z Score
Intestinal Function by lactulose:mannitol
Characterization of strains causing rotavirus gastroenteritis
Incidence of adverse events

Full Information

First Posted
December 21, 2010
Last Updated
February 3, 2015
Sponsor
Christian Medical College, Vellore, India
Collaborators
Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT01265355
Brief Title
Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement
Official Title
Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement
Study Type
Interventional

2. Study Status

Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Christian Medical College, Vellore, India
Collaborators
Karolinska Institutet

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rotavirus is the commonest cause of severe gastroenteritis in young children worldwide. The investigators hypothesize that use of a food based prophylactic will decrease incidence of rotavirus infection in young children in south India, prevent intestinal damage and overall result in lower infection rates and better gut function. This trial will evaluate the efficacy of prevention of rotavirus gastroenteritis when an anti-rotavirus protein or antibody fragments expressed in yeast or placebo are given daily as a food supplement to children between the ages of 6 and 12 months. The children will followed for one year and rates of rotavirus diarrhoea, antibody responses and gut function will be compared between children receiving antibody fragments or placebo.
Detailed Description
The study will be carried out in an urban slum area in Vellore, south India. Children between the ages of 6 and 12 months will be recruited for participation in the study. They will be randomized to receive supplementation with ARP or placebo, and will be followed for a period of one year, with weekly home visits and monitoring of all episodes of diarrhoea. In addition, every two weeks, surveillance stool samples will be collected and tested for rotavirus to identify asymptomatic infections by PCR. All episodes of diarrhoea will be investigated intensively for bacterial, viral and parasitic agents of diarrhoea using both conventional and molecular techniques and all cases will be treated appropriately at the study clinic or referral hospital as required. Monthly anthropometric measurements will be carried out to estimate rates of growth and to identify growth faltering. Blood samples will be taken at 4, 8 and 12 months for estimation of anti-rotavirus IgA and IgG antibodies. Studies on intestinal absorption and permeability will be carried out at recruitment, 6 and 12 months by the lactulose:mannitol test (measured by HPLC detection of sugars). All rotavirus strains obtained will be characterized by genotyping.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotavirus Gastroenteritis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
330 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Anti-rotavirus protein
Arm Type
Experimental
Arm Title
Maltodextrin
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Anti-rotavirus protein
Intervention Description
11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin
Intervention Description
Maltodextrin 1 gm daily
Primary Outcome Measure Information:
Title
Incidence of rotavirus gastroenteritis
Time Frame
One year after recruitment
Secondary Outcome Measure Information:
Title
IgA And IgG Antibody Response To Rotavirus
Time Frame
At 4, 8 And 12 Months after recruitment
Title
Weight For Height Z Score
Time Frame
At 6 and 12 months after recruitment
Title
Intestinal Function by lactulose:mannitol
Time Frame
at 3, 6, 9 and 12 months
Title
Characterization of strains causing rotavirus gastroenteritis
Time Frame
Over 12 months
Title
Incidence of adverse events
Time Frame
Over 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
12 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year Normal birth weight (> 2.5 kg), child exclusively breast fed for at least four months Exclusion Criteria: Families not available for a follow up period of one year Children with any atopic conditions Children with gross congenital anomalies including cardiovascular, renal or hepatic disease Children with syndromic or serological evidence of HIV infection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gagandeep Kang, MD
Organizational Affiliation
Christian Medical College, Vellore, India
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Uma Raman, MDS
Organizational Affiliation
Christian Medical College, Vellore, India
Official's Role
Study Director
Facility Information:
Facility Name
Christian Medical College
City
Vellore
State/Province
TN
ZIP/Postal Code
632004
Country
India

12. IPD Sharing Statement

Learn more about this trial

Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement

We'll reach out to this number within 24 hrs